Agreements signed in Greece, Latvia, Lithuania and Kuwait, with more in discussions Mobidiag Ltd.announced today that it has signed multiple…
Mobidiag Ltd. today announces the completion of the €10m equity investment from Autobio Diagnostics (‘Autobio’), as announced on 18 December…
Discover a new article in which our CEO Tuomas Tenkanen presents Mobidiag solutions for antibiotic resistance and the recent news…
Our CEO Tuomas Tenkanen has been interviewed by the Finnish Magazine Talouselämä to talk about the exciting latest news at…
CE-IVD marking of Novodiag® CarbaR+, the 3rd molecular test on the automated system Novodiag®, for detection of the main Carbapenemase-Producing…
The article presents the results of the multicentric prospective study carried out in the framework of the Hepystool Hospital Clinical…
Mobidiag has entered into a joint venture agreement with Autobio Diagnostics, one of the leading clinical diagnostics companies in China,…
Mobidiag will host a symposium at the 38th Interdisciplinary Meeting of Anti-Infectious Chemotherapy (RICAI), in Paris this month. Mobidiag will…
In the scope of the World Antibiotic Awareness Week 2018, Bpifrance (French Public Investment Bank) has highlighted the French key…
Mobidiag announced today that it has received the final €4M tranche of a €15M three-year project secured by the Company…